Fig 1.

Overexpression of cyclin A2 was associated with resistance to chemotherapy in endometrial carcinoma tissue and cell lines. (A) The expression of cyclin A2 and cyclin E1 protein extracted from normal endometrium (case no. 1–4), and early-stage (stage I, case no. 5–13), advanced-stage (stages II–III, case no. 14–21) and chemotherapy-refractory (case no. 22–26) endometrial carcinoma specimens using Western blotting. (B) The densitometric quantification of cyclin A2 and cyclin E1 protein expression relative to β-actin (relative expression) as shown in Fig. 1A. The expression of cyclin A2 was increased, especially in advanced-stage tumours and refractory tumours. In contrast, the expression of cyclin E1 was decreased in refractory tumours (NE, normal endometrium; CA, carcinoma; *P < 0.05) (C) The expression of endogenous cyclin A2 protein in various endometrial carcinoma cell lines. (D) The expression of endogenous cyclin A2 was strongly (R= 0.908) correlated with the median inhibitory concentration (IC₅₀) for cisplatin (CDDP, P < 0.05). (E) The correlation of endogenous cyclin A2 expression with the IC₅₀ for adriamycin (ADM). (F) The correlation of endogenous cyclin A2 expression with the IC₅₀ for paclitaxel (PTX). There was no significant correlation between cyclin A2 and IC₅₀ for adriamycin or paclitaxel.